Disappointingly, a phase III clinical trial that aimed to evaluate the effectiveness of Rova-T versus topotecan as a second-line treatment for advanced SCLC patients with high levels of DLL3 was halted prematurely due to a reduction in overall survival in the Rova-T arm [31]. This evidence concerns the gene DLL3 and small cell lung carcinoma.